Cantor Fitzgerald Believes BioDelivery (BDSI) Still Has Room to Grow
Cantor Fitzgerald analyst Brandon Folkes reiterated a Buy rating on BioDelivery (NASDAQ: BDSI) today and set a price target of $4.50. The company’s shares closed on Friday at $2.96, close to its 52-week high of $3.20.
“. NYC, we are reiterating our Overweight rating and 12-month price target of $4.50. BDSI continues to evolve into a commercial-stage company with solid growth from its lead product, Belbuca. Fundamentally, BDSI continues to perform very well, and with a focused execution strategy and the funds to implement that strategy, we believe that investors will be rewarded by the company’s solid execution in 2018 and beyond.”
According to TipRanks.com, Folkes is a 1-star analyst with an average return of -2.2% and a 38.3% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Opiant Pharmaceuticals Inc, and Eagle Pharmaceuticals Inc.
BioDelivery has an analyst consensus of Strong Buy, with a price target consensus of $4.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.20 and a one-year low of $1.70. Currently, BioDelivery has an average volume of 380.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioDelivery Sciences International, Inc. is a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction.